Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Travera Inc
With
Dana-Farber Cancer Institute
Massachusetts General Hospital
Weill Medical College of Cornell University
City of Hope Medical Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Written Informed Consent provided by patient
2. MM, with the following conditions:
(CLOSED) \*For patients in the Vanguard cohort\*
1\. Treatment naïve disease with BM clinically indicated
\*For patients in the RRMM cohort\*
1. Relapsed/refractory disease with BM samples clinically indicated
2. Within 4-weeks prior to initiation of 2nd-line or later therapy
3. Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)
You may not be if
1. Unable or unwilling to provide informed consent
2. Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)
3. Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study
4. Prior exposure to CAR-T therapy
5. Prior allogeneic stem cell transplant
6. Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy
7. Has received any Ab therapy within 4 weeks prior to BM biopsy